Gilead's lenacapavir long-acting HIV PrEP is a category-redefining product approved for twice-yearly dosing, with strong real-world uptake. The HIV franchise is stable with Biktarvy LOE not until 2033. Oncology pipeline from Immunomedics is finally showing late-stage progress. Trodelvy in first-line TNBC reads out in 2026.
Thesis reviewed May 29, 2026
Gilead Sciences Inc. is headquartered in United States, which is currently showing elevated risk signals.
🇺🇸United States82EXITView United States risk detail →💊Pharma0NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| AZN | AstraZeneca PLC | 50 | +11% | ↓0% | EARLY |
| JNJ | Johnson & Johnson | 50 | +8% | ↓0% | NEUTRAL |
| REGN | Regeneron Pharmaceuticals Inc. | 50 | -16% | ↓0% | AVOID |
| TAK | Takeda Pharmaceutical Company Limited | 50 | +10% | ↓0% | NEUTRAL |
| LLY | Eli Lilly and Company | 50 | +24% | ↓0% | EARLY |
| PFE | Pfizer Inc. | 50 | +6% | ↓0% | NEUTRAL |
| NVO | Novo Nordisk A/S | 50 | +15% | ↓0% | EARLY |
Investors who hold GILD may also have indirect exposure through these country funds.
Lenacapavir PrEP gains WHO prequalification, Global Fund commits volume
Trodelvy ASCENT-04 first-line TNBC enrolls ahead of plan
Gilead HIV pricing power preserved in latest IRA round
Estimates · Yahoo Finance · Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Alan Armstrong | Buy | $1k–$15k | Mar 27, 26 | ||
| Jared MoskowitzFL | Buy | $1k–$15k | May 6, 26 | ||
| Josh GottheimerNJ | D | Buy | $1k–$15k | Jan 27, 26 | -6.0% |
| John Boozman | Sell | $1k–$15k | Apr 16, 25 | +40.3% | |
| Marjorie Taylor Mrs GreeneGA | R | Buy | $1k–$15k | Dec 24, 24 | +47.7% |
| Thomas H Tuberville | Buy | $1k–$15k | May 10, 24 | +117.4% | |
| Thomas H Tuberville | Sell | $1k–$15k | May 8, 24 | +117.4% |